Common Contracts
8 similar Underwriting Agreement contracts by Allegiance Bancshares, Inc., Auris Medical Holding AG, Biosante Pharmaceuticals Inc, others
7,016,312 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 3,483,688 Shares of Common Stock ($0.001 par value per share) KalVista Pharmaceuticals, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 16th, 2024 • KalVista Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
BRAINSWAY LTD. 4,622,000 American Depositary Shares Representing an Aggregate of 9,244,000 Ordinary Shares (par value NIS 0.04 per share) Underwriting AgreementUnderwriting Agreement • February 25th, 2021 • Brainsway Ltd. • Surgical & medical instruments & apparatus • New York
The ADSs will be evidenced by American Depositary Receipts (“ADRs”) issued pursuant to that certain Deposit Agreement to be dated on or prior to April 22, 2019 (the “Deposit Agreement”), by and among the Company, The Bank of New York Mellon, as depositary (the “Depositary”), and all holders and beneficial owners of ADSs issued thereunder. The Company shall, following subscription by the Underwriters of the Offered Shares pursuant to this Agreement, deposit, on behalf of the Underwriters, the Ordinary Shares being delivered in the form of the Offered Shares with Bank Leumi as custodian (the “Custodian”) for the Depositary, which shall deliver the Offered Shares to the Representative for the account of the several Underwriters for subsequent delivery to the other several Underwriters or the investors, as the case may be. Unless the context otherwise requires, each reference to the Offered Shares or ADSs herein also includes the Ordinary Shares and the ADRs evidencing such ADSs.
Xeris Pharmaceuticals, Inc. 5.00% Convertible Senior Notes due 2025 UNDERWRITING AGREEMENTUnderwriting Agreement • June 29th, 2020 • Xeris Pharmaceuticals Inc • Pharmaceutical preparations • New York
HELIUS MEDICAL TECHNOLOGIES, INC. 2,141,900 Shares of Class A Common Stock and 2,141,900 Warrants Underwriting AgreementUnderwriting Agreement • April 12th, 2018 • Helius Medical Technologies, Inc. • Electromedical & electrotherapeutic apparatus • New York
Helius Medical Technologies, Inc., a Wyoming corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 2,141,900 shares of its Class A Common Stock, no par value per share (the “Shares”) and warrants (the “Warrants” and, together with the Shares, the “Firm Securities”) to purchase 2,141,900 shares of its Class A Common Stock. In addition, the Company has granted to BTIG (as defined below) an option to purchase, in the aggregate, up to an additional 321,285 Shares (the “Option Shares”) and Warrants to purchase up to 321,285 Shares (the “Option Warrants” and, collectively with the Option Shares, the “Option Securities”) which may be purchased in any combination of Option Shares and/or Option Warrants. The shares of Class A Common Stock underlying the Warrants and Option Warrants are hereinafter referred to as the “Warrant Shares.” The Firm Securities and, if and to the extent such option is exercised, the
Erytech Pharma S.A. [Number of Shares] Ordinary Shares and [Number of ADSs] American Depositary Shares Each Representing One Ordinary Share (Nominal Value €0.10 Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • November 8th, 2017 • Erytech Pharma S.A. • Biological products, (no disgnostic substances) • New York
Shares ALLEGIANCE BANCSHARES, INC. COMMON STOCK ($1.00 par value per share) UNDERWRITING AGREEMENTUnderwriting Agreement • September 28th, 2015 • Allegiance Bancshares, Inc. • State commercial banks • New York
Allegiance Bancshares, Inc., a Texas corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), subject to the terms and conditions stated herein, an aggregate of shares of the common stock, $1.00 par value per share of the Company (the “Firm Shares”).
● ] Common Shares Auris Medical Holding AG UNDERWRITING AGREEMENTUnderwriting Agreement • May 4th, 2015 • Auris Medical Holding AG • Pharmaceutical preparations • New York
Die Unterzeichnende verpflichtet sich hiermit bedingungslos, eine dem Ausgabebetrag entsprechende Einlage der gezeichneten Aktien zu leisten.
16,000,000 Shares BioSante Pharmaceuticals, Inc. Common Stock, $0.0001 Par Value per Share UNDERWRITING AGREEMENTUnderwriting Agreement • July 28th, 2011 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Introductory. BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 16,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”). The 16,000,000 shares of Common Stock to be sold by the Company are collectively called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,400,000 shares of Common Stock as provided in Section 2. The additional 2,400,000 shares of Common Stock to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies & Company, Inc. (“Jefferies”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the o
